226 related articles for article (PubMed ID: 30418623)
1. Podoplanin expression is a prognostic biomarker but may be dispensable for the malignancy of glioblastoma.
Eisemann T; Costa B; Harter PN; Wick W; Mittelbronn M; Angel P; Peterziel H
Neuro Oncol; 2019 Feb; 21(3):326-336. PubMed ID: 30418623
[TBL] [Abstract][Full Text] [Related]
2. Suppressing Dazl modulates tumorigenicity and stemness in human glioblastoma cells.
Zhang F; Liu R; Zhang H; Liu C; Liu C; Lu Y
BMC Cancer; 2020 Jul; 20(1):673. PubMed ID: 32682409
[TBL] [Abstract][Full Text] [Related]
3. miR-29b and miR-125a regulate podoplanin and suppress invasion in glioblastoma.
Cortez MA; Nicoloso MS; Shimizu M; Rossi S; Gopisetty G; Molina JR; Carlotti C; Tirapelli D; Neder L; Brassesco MS; Scrideli CA; Tone LG; Georgescu MM; Zhang W; Puduvalli V; Calin GA
Genes Chromosomes Cancer; 2010 Nov; 49(11):981-90. PubMed ID: 20665731
[TBL] [Abstract][Full Text] [Related]
4. p53 upregulated modulator of apoptosis sensitizes drug-resistant U251 glioblastoma stem cells to temozolomide through enhanced apoptosis.
Miao W; Liu X; Wang H; Fan Y; Lian S; Yang X; Wang X; Guo G; Li Q; Wang S
Mol Med Rep; 2015 Jun; 11(6):4165-73. PubMed ID: 25625235
[TBL] [Abstract][Full Text] [Related]
5. ChLpMab-23: Cancer-Specific Human-Mouse Chimeric Anti-Podoplanin Antibody Exhibits Antitumor Activity via Antibody-Dependent Cellular Cytotoxicity.
Kaneko MK; Nakamura T; Kunita A; Fukayama M; Abe S; Nishioka Y; Yamada S; Yanaka M; Saidoh N; Yoshida K; Fujii Y; Ogasawara S; Kato Y
Monoclon Antib Immunodiagn Immunother; 2017 Jun; 36(3):104-112. PubMed ID: 28504613
[TBL] [Abstract][Full Text] [Related]
6. CIS deletion by CRISPR/Cas9 enhances human primary natural killer cell functions against allogeneic glioblastoma.
Nakazawa T; Morimoto T; Maeoka R; Matsuda R; Nakamura M; Nishimura F; Ouji N; Yamada S; Nakagawa I; Park YS; Ito T; Nakase H; Tsujimura T
J Exp Clin Cancer Res; 2023 Aug; 42(1):205. PubMed ID: 37563692
[TBL] [Abstract][Full Text] [Related]
7. Aspirin Affects Tumor Angiogenesis and Sensitizes Human Glioblastoma Endothelial Cells to Temozolomide, Bevacizumab, and Sunitinib, Impairing Vascular Endothelial Growth Factor-Related Signaling.
Navone SE; Guarnaccia L; Cordiglieri C; Crisà FM; Caroli M; Locatelli M; Schisano L; Rampini P; Miozzo M; La Verde N; Riboni L; Campanella R; Marfia G
World Neurosurg; 2018 Dec; 120():e380-e391. PubMed ID: 30144594
[TBL] [Abstract][Full Text] [Related]
8. In vivo CRISPR screening for novel noncoding RNA functional targets in glioblastoma models.
Attenello FJ; Tsung K; Bishara I; Loh YE; Chen TC
J Neurosci Res; 2021 Sep; 99(9):2029-2045. PubMed ID: 33969526
[TBL] [Abstract][Full Text] [Related]
9. Transcriptional targeting of adenovirally delivered tumor necrosis factor alpha by temozolomide in experimental glioblastoma.
Yamini B; Yu X; Gillespie GY; Kufe DW; Weichselbaum RR
Cancer Res; 2004 Sep; 64(18):6381-4. PubMed ID: 15374943
[TBL] [Abstract][Full Text] [Related]
10. Podoplanin increases migration and angiogenesis in malignant glioma.
Grau SJ; Trillsch F; Tonn JC; Goldbrunner RH; Noessner E; Nelson PJ; von Luettichau I
Int J Clin Exp Pathol; 2015; 8(7):8663-70. PubMed ID: 26339454
[TBL] [Abstract][Full Text] [Related]
11. The HIF‑1α/miR‑224‑3p/ATG5 axis affects cell mobility and chemosensitivity by regulating hypoxia‑induced protective autophagy in glioblastoma and astrocytoma.
Huang S; Qi P; Zhang T; Li F; He X
Oncol Rep; 2019 Mar; 41(3):1759-1768. PubMed ID: 30569180
[TBL] [Abstract][Full Text] [Related]
12. The TNF receptor family member Fn14 is highly expressed in recurrent glioblastoma and in GBM patient-derived xenografts with acquired temozolomide resistance.
Hersh DS; Harder BG; Roos A; Peng S; Heath JE; Legesse T; Kim AJ; Woodworth GF; Tran NL; Winkles JA
Neuro Oncol; 2018 Sep; 20(10):1321-1330. PubMed ID: 29897522
[TBL] [Abstract][Full Text] [Related]
13. Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway.
Yu X; Wang M; Zuo J; Wahafu A; Mao P; Li R; Wu W; Xie W; Wang J
Life Sci; 2019 Nov; 236():116917. PubMed ID: 31614149
[TBL] [Abstract][Full Text] [Related]
14. Long non-coding RNA TUSC7 inhibits temozolomide resistance by targeting miR-10a in glioblastoma.
Shang C; Tang W; Pan C; Hu X; Hong Y
Cancer Chemother Pharmacol; 2018 Apr; 81(4):671-678. PubMed ID: 29397407
[TBL] [Abstract][Full Text] [Related]
15. Podoplanin increases the migration of human fibroblasts and affects the endothelial cell network formation: A possible role for cancer-associated fibroblasts in breast cancer progression.
Suchanski J; Tejchman A; Zacharski M; Piotrowska A; Grzegrzolka J; Chodaczek G; Nowinska K; Rys J; Dziegiel P; Kieda C; Ugorski M
PLoS One; 2017; 12(9):e0184970. PubMed ID: 28938000
[TBL] [Abstract][Full Text] [Related]
16. Revealing Temozolomide Resistance Mechanisms via Genome-Wide CRISPR Libraries.
Rocha CRR; Reily Rocha A; Molina Silva M; Rodrigues Gomes L; Teatin Latancia M; Andrade Tomaz M; de Souza I; Karolynne Seregni Monteiro L; Menck CFM
Cells; 2020 Dec; 9(12):. PubMed ID: 33271924
[TBL] [Abstract][Full Text] [Related]
17. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
[TBL] [Abstract][Full Text] [Related]
18. A transcriptomic signature mediated by HOXA9 promotes human glioblastoma initiation, aggressiveness and resistance to temozolomide.
Pojo M; Gonçalves CS; Xavier-Magalhães A; Oliveira AI; Gonçalves T; Correia S; Rodrigues AJ; Costa S; Pinto L; Pinto AA; Lopes JM; Reis RM; Rocha M; Sousa N; Costa BM
Oncotarget; 2015 Apr; 6(10):7657-74. PubMed ID: 25762636
[TBL] [Abstract][Full Text] [Related]
19. YES1 Drives Lung Cancer Growth and Progression and Predicts Sensitivity to Dasatinib.
Garmendia I; Pajares MJ; Hermida-Prado F; Ajona D; Bértolo C; Sainz C; Lavín A; Remírez AB; Valencia K; Moreno H; Ferrer I; Behrens C; Cuadrado M; Paz-Ares L; Bustelo XR; Gil-Bazo I; Alameda D; Lecanda F; Calvo A; Felip E; Sánchez-Céspedes M; Wistuba II; Granda-Diaz R; Rodrigo JP; García-Pedrero JM; Pio R; Montuenga LM; Agorreta J
Am J Respir Crit Care Med; 2019 Oct; 200(7):888-899. PubMed ID: 31166114
[No Abstract] [Full Text] [Related]
20. MPC1 deletion is associated with poor prognosis and temozolomide resistance in glioblastoma.
Chai Y; Wang C; Liu W; Fan Y; Zhang Y
J Neurooncol; 2019 Sep; 144(2):293-301. PubMed ID: 31236818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
